STOCK TITAN

Vanguard amends 13G/A; reports 0 shares in Alnylam (ALNY)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Alnylam Pharmaceuticals Inc: Amendment No. 10 to a Schedule 13G/A filed by The Vanguard Group reports zero shares beneficially owned of Alnylam common stock and 0% ownership as disclosed in the form. The filing includes a statement that Vanguard reorganized certain subsidiaries on January 12, 2026, and those entities will report separately following SEC Release No. 34-39538.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership after internal realignment.

The filing states 0 shares beneficially owned and 0% of the class, indicating Vanguard does not hold reportable beneficial ownership in Alnylam via the reporting entity named here as of the amended filing.

The disclosure notes an internal realignment effective January 12, 2026, with subsidiaries to report separately under SEC Release No. 34-39538; subsequent filings by those subsidiaries may show separate positions.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Vanguard report in the Schedule 13G/A for ALNY?

The filing reports zero shares beneficially owned and 0% ownership of Alnylam common stock by The Vanguard Group as stated in the amendment. It reflects Vanguard's reporting entity position only and notes an internal reorganization on January 12, 2026.

Does this Schedule 13G/A mean Vanguard has no connection to ALNY holdings?

This filing shows the named Vanguard reporting entity holds 0 shares and 0%. The filing also explains certain Vanguard subsidiaries now report separately; those separate reports could reflect holdings not shown under this specific filing.

What is the significance of the January 12, 2026 realignment mentioned?

The realignment caused certain Vanguard subsidiaries or divisions to report beneficial ownership separately in reliance on SEC Release No. 34-39538. That means reporting is disaggregated; ownership previously reported under Vanguard may appear in separate filings by those entities.

Who signed the amended Schedule 13G/A for ALNY and when?

The amendment was signed by Ashley Grim, Head of Global Fund Administration for The Vanguard Group, with a signature date of 03/26/2026, certifying the ownership statements contained in the form.

Will future filings show Vanguard ownership in ALNY after this amendment?

This amendment reflects the named Vanguard entity's position as 0 shares. The filing states subsidiaries will report separately, so future Schedule 13 filings by those subsidiaries may disclose positions that are not reported under this specific Vanguard entity.
Alnylam Pharmaceuticals Inc

NASDAQ:ALNY

View ALNY Stock Overview

ALNY Rankings

ALNY Latest News

ALNY Latest SEC Filings

ALNY Stock Data

43.52B
131.71M
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE